Anti-RFLNB monoclonal antibody

Pre-made anti-RFLNB monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to RFLNB/RFLNB products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2697-Ab-1/ GM-Tg-hg-IP2697-Ab-2Anti-Human RFLNB monoclonal antibodyHuman
GM-Tg-rg-IP2697-Ab-1/ GM-Tg-rg-IP2697-Ab-2Anti-Rat RFLNB monoclonal antibodyRat
GM-Tg-mg-IP2697-Ab-1/ GM-Tg-mg-IP2697-Ab-2Anti-Mouse RFLNB monoclonal antibodyMouse
GM-Tg-cynog-IP2697-Ab-1/ GM-Tg-cynog-IP2697-Ab-2Anti-Cynomolgus/ Rhesus macaque RFLNB monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2697-Ab-1/ GM-Tg-felg-IP2697-Ab-2Anti-Feline RFLNB monoclonal antibodyFeline
GM-Tg-cang-IP2697-Ab-1/ GM-Tg-cang-IP2697-Ab-2Anti-Canine RFLNB monoclonal antibodyCanine
GM-Tg-bovg-IP2697-Ab-1/ GM-Tg-bovg-IP2697-Ab-2Anti-Bovine RFLNB monoclonal antibodyBovine
GM-Tg-equg-IP2697-Ab-1/ GM-Tg-equg-IP2697-Ab-2Anti-Equine RFLNB monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2697-Ab-1/ GM-Tg-hg-IP2697-Ab-2; GM-Tg-rg-IP2697-Ab-1/ GM-Tg-rg-IP2697-Ab-2;
GM-Tg-mg-IP2697-Ab-1/ GM-Tg-mg-IP2697-Ab-2; GM-Tg-cynog-IP2697-Ab-1/ GM-Tg-cynog-IP2697-Ab-2;
GM-Tg-felg-IP2697-Ab-1/ GM-Tg-felg-IP2697-Ab-2; GM-Tg-cang-IP2697-Ab-1/ GM-Tg-cang-IP2697-Ab-2;
GM-Tg-bovg-IP2697-Ab-1/ GM-Tg-bovg-IP2697-Ab-2; GM-Tg-equg-IP2697-Ab-1/ GM-Tg-equg-IP2697-Ab-2
Products NameAnti-RFLNB monoclonal antibody
Formatmab
Target NameRFLNB
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-RFLNB monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2697-Ag-1Recombinant multi-species RFLB/ RFLNB/ CFM1 protein
    ORF Viral VectorvGMLP003454human RFLNB Lentivirus particle
    ORF Viral VectorpGMLP003454human RFLNB Lentivirus plasmid


    Target information

    Target IDGM-IP2697
    Target NameRFLNB
    Gene ID359845,76566,287534,699332,611214,101087112,112442617,100072318
    Gene Symbol and Synonyms1500005K14Rik,cfm,CFM1,FAM101B,RefilinB,RFLNB,RGD1359691
    Uniprot AccessionQ8N5W9,Q6AXS9
    Uniprot Entry NameRFLB_HUMAN,RFLB_RAT
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000183688
    Target ClassificationN/A

    The target: RFLNB, gene name: RFLNB, also named as CFM1, FAM101B. Enables filamin binding activity. Predicted to be involved in several processes, including actin filament bundle organization; negative regulation of bone mineralization involved in bone maturation; and negative regulation of chondrocyte development. Predicted to act upstream of or within actin cytoskeleton organization and epithelial to mesenchymal transition. Predicted to be located in actin cytoskeleton. Predicted to be active in actin filament bundle. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.